Euronext

Galapagos announces full year 2023 results and outlook for 2024

Retrieved on: 
Thursday, February 22, 2024
Technology transfer, CD19, Filgotinib, Lupus, Multiple myeloma, DL2, Dermatomyositis, Acceleration, Baltic, BCMA, Mantle cell lymphoma, European Commission, Indolent lymphoma, JAK1, Safety, EBMT, RT, TYK2, CFO, PRAC, MAA, Richter's transformation, Euronext, Executive Committee, JAK, UC, Patient, SLE, Pharmaceutical industry

In addition, we entered into a strategic collaboration with BridGene Biosciences to advance our growing early-stage pipeline in precision oncology.

Key Points: 
  • In addition, we entered into a strategic collaboration with BridGene Biosciences to advance our growing early-stage pipeline in precision oncology.
  • Signed an agreement with Boston-based Landmark Bio and started the technology transfer for the decentralized production of Galapagos’ CAR-T cell therapy candidates.
  • Further streamlined our operations with a reduction of approximately 100 positions across the Galapagos organization to align with the Galapagos’ renewed focus on innovation.
  • Signed a strategic collaboration and license agreement with BridGene Biosciences to further strengthen Galapagos' growing early-stage oncology precision medicine pipeline.

argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024

Retrieved on: 
Thursday, February 22, 2024
Webcast, Euronext

Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, February 29, 2024 at 2:30 PM CET (8:30 AM ET) to discuss its full year 2023 financial results and provide a fourth quarter business update.

Key Points: 
  • Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, February 29, 2024 at 2:30 PM CET (8:30 AM ET) to discuss its full year 2023 financial results and provide a fourth quarter business update.
  • A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors .
  • A replay of the webcast will be available on the argenx website for approximately one year following the presentation.

argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy

Retrieved on: 
Tuesday, February 20, 2024
Neonatal Fc receptor, Chronic inflammatory demyelinating polyneuropathy, Autoimmune disease, CIDP, FDA, Food, ECI, PDUFA, Euronext, Risk, Autoantibody, Safety, Immunoglobulin G, Patient, Clinical trial, Biology, Pharmaceutical industry

“Today’s announcement brings us one step closer to delivering the transformative innovation of VYVGART Hytrulo to CIDP patients,” said Luc Truyen, Chief Medical Officer of argenx.

Key Points: 
  • “Today’s announcement brings us one step closer to delivering the transformative innovation of VYVGART Hytrulo to CIDP patients,” said Luc Truyen, Chief Medical Officer of argenx.
  • We chose to use a priority review voucher to accelerate review of our submission because CIDP patients have long been waiting for new treatment options.
  • In the open-label Stage A of the study, 67% of patients showed evidence of clinical improvement (ECI) following treatment with VYVGART Hytrulo.
  • VYVGART Hytrulo was well-tolerated with a safety profile that is consistent with prior clinical trials and the known profile of VYVGART®.

Citycon announces the results of its tender offer for the outstanding notes of Citycon Treasury B.V. due 2024

Retrieved on: 
Tuesday, March 5, 2024
ACT, Attention, Offer and acceptance, ITS, WAKE, Euronext Dublin, Surety, Person, Capital market, Euronext, Note, ANY, Settlement date, Offer, Telephone, EUR, NOT, Interest, Tender, AS, Security (finance)

HELSINKI, March 5, 2024 /PRNewswire/ -- On 27 February 2024, Citycon Treasury B.V. (the "Offeror") launched an invitation to holders of its EUR 310,342,000 2.50 per cent Guaranteed Notes due 2024 guaranteed by Citycon Oyj (the "Guarantor") (ISIN: XS1114434167) issued in separate tranches on 1 October 2014 and 10 June 2020 (the "Securities"), to tender any and all of their Securities for purchase by the Offeror for cash (the "Offer") on the terms and subject to the conditions set out in the tender offer memorandum dated 27 February 2024 (the "Tender Offer Memorandum") prepared by the Offeror, including the satisfaction (or waiver) of the Financing Condition, being the successful completion (in the sole determination of the Offeror) of the issue of the New Notes (as defined below). The Offer remains subject to the offer and distribution restrictions set out in the Tender Offer Memorandum.Capitalised terms used in this announcement but not defined have the meanings given to them in the Tender Offer Memorandum.On 28 February 2024, the Offeror priced its EUR 300 million 6.500 per cent. Senior Unsecured Green Notes due 2029 (the "New Notes"). The New Notes are unconditionally and irrevocably guaranteed by the Guarantor. Application will be made for the New Notes to be admitted to listing and trading on the Irish Stock Exchange plc trading as Euronext Dublin. The New Notes are expected to settle on 6 March 2024. The Offeror today announces that, subject to the satisfaction (or waiver) of the Financing Condition, it will accept for purchase EUR 213,253,000 in aggregate principal amount of Securities validly tendered pursuant to the Offer. The total purchase consideration (including Accrued Interest Payments) for Securities validly tendered and accepted for purchase pursuant to the Offer will be EUR 213,688,537.15, which will be funded using a portion of the net proceeds from the New Notes.

Key Points: 
  • The Offer remains subject to the offer and distribution restrictions set out in the Tender Offer Memorandum.
  • Capitalised terms used in this announcement but not defined have the meanings given to them in the Tender Offer Memorandum.
  • Full details concerning the Offer are set out in the Tender Offer Memorandum.
  • The distribution of this announcement and the Tender Offer Memorandum in certain jurisdictions may be restricted by law.

Sartorius Stedim Biotech releases Universal Registration Document 2023

Retrieved on: 
Friday, February 16, 2024
Sartorius AG, Annual, Euronext, Euronext Paris

Sartorius Stedim Biotech, a leading partner of the biopharma industry, has released its Universal Registration Document 2023 including the Annual Financial Report today.

Key Points: 
  • Sartorius Stedim Biotech, a leading partner of the biopharma industry, has released its Universal Registration Document 2023 including the Annual Financial Report today.
  • Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry.
  • The shares of Sartorius Stedim Biotech S.A. are quoted on the Euronext Paris.
  • Sartorius Stedim Biotech regularly expands its portfolio through acquisitions of complementary technologies.

Sartorius Stedim Biotech: Information on Document Availability

Retrieved on: 
Friday, February 16, 2024
Sartorius AG, Bank statement, Euronext, Euronext Paris

The issuer is solely responsible for the content of this announcement.

Key Points: 
  • The issuer is solely responsible for the content of this announcement.
  • Sartorius Stedim Biotech Group’s Universal Registration Document 2023 is now available at:
    It contains the following information:
    - Consolidated financial statements for the year ended December 31, 2023
    Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry.
  • The shares of Sartorius Stedim Biotech S.A. are quoted on the Euronext Paris.
  • Sartorius Stedim Biotech regularly expands its portfolio through acquisitions of complementary technologies.

Nyxoah to Release Fourth Quarter and Financial Year 2023 Financial Results on March 5, 2024

Retrieved on: 
Thursday, February 15, 2024
Obstructive sleep apnea, Finance, Euronext, Webcast, Fiscal year, OSA, Mont-Saint-Guibert

Nyxoah to Release Fourth Quarter and Financial Year 2023 Financial Results on March 5, 2024

Key Points: 
  • Nyxoah to Release Fourth Quarter and Financial Year 2023 Financial Results on March 5, 2024
    Mont-Saint-Guibert, Belgium – February 15, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will release financial results for the fourth quarter and financial year 2023 on Tuesday, March 5, 2024, after market close.
  • Company management will host a conference call to discuss financial results that day beginning at 10:30pm CET / 4:30pm ET.
  • A webcast of the call will be accessible via the Investor Relations page of the Nyxoah website or through this link: Nyxoah's Q4 2023 earnings call webcast .
  • If you plan to ask a question, please use the following link: Nyxoah’s Q4 2023 earnings call .

Galapagos presents at EBMT-EHA annual meeting 2024

Retrieved on: 
Thursday, February 15, 2024
Blood, Galapagos NV, European, Safety, Richter's transformation, CD19, Euronext, Multiple myeloma, EHA, DL2, EBMT, RT, Patient, Efficacy

Mechelen, Belgium; 15 February 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) to present new preliminary translational data and previously disclosed data at the European Society for Blood and Marrow Transplantation (EBMT)-European Hematology Association (EHA) 6th European CAR T-cell meeting taking place from 15–17 February 2024 in Valencia, Spain.

Key Points: 
  • Mechelen, Belgium; 15 February 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) to present new preliminary translational data and previously disclosed data at the European Society for Blood and Marrow Transplantation (EBMT)-European Hematology Association (EHA) 6th European CAR T-cell meeting taking place from 15–17 February 2024 in Valencia, Spain.
  • Further, previously disclosed safety, efficacy and feasibility data from EUPLAGIA-1 and ATALANTA-1 support the potential of Galapagos’ innovative approach to CAR-T manufacturing and of the transformational impact on patients with severe hematologic cancers.
  • “At Galapagos, we are committed to accelerating transformative innovation to address the unmet needs of patients with advanced cancers, and the data we are presenting today demonstrates our positive momentum toward this goal,” said Dr Jeevan Shetty, M.D., Head of Clinical Development Oncology at Galapagos.
  • Moreover, the abundance of both CD4+ and CD8+ TN/SCM CAR-T cells in the final product correlated with CAR-T-cell exposure in patients.

InterDigital and Broadpeak Announce Collaboration on MPEG V3C Standardized Content Distribution At Scale

Retrieved on: 
Tuesday, February 13, 2024
EVP, InterDigital, AI, Mobile, CDN, Euronext, Mobile World Congress, ARPU, Coding, Research, MPEG, IDCC, Television

Volumetric video is a critical component in the creation and enjoyment of increasingly immersive experiences and the MPEG V3C standard defines the general mechanism for coding and streaming volumetric content.

Key Points: 
  • Volumetric video is a critical component in the creation and enjoyment of increasingly immersive experiences and the MPEG V3C standard defines the general mechanism for coding and streaming volumetric content.
  • The wide-scale distribution of volumetric content to broad audiences also depends on efficient and V3C-compliant distribution networks, and this is a key area of focus for the InterDigital-Broadpeak collaboration.
  • InterDigital will contribute the V3C end-to-end implementation platform built jointly with its partner Philips, and Broadpeak will contribute on packaging and content delivery network (CDN) technologies.
  • “Thanks to our collaboration with InterDigital, we will further enhance our Origin-Packager and CDN to stream standardized V3C volumetric content to wide audiences.”
    InterDigital and Broadpeak will showcase the latest results of their collaboration on immersive content distribution at scale at Mobile World Congress in Barcelona from February 26 – 29.

KBC Securities Initiates Research Coverage of ONWARD® Medical with a Buy Rating and Target Price of EUR 10.00 Per Share

Retrieved on: 
Friday, February 9, 2024
KBC, Target, Target price, Buy, Euronext, BCI, Movement, EUR, SCI, ARC, Research, Cryptocurrency

EINDHOVEN, the Netherlands, Feb. 09, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announced that KBC Securities, part of the KBC Group -- a leading Belgian integrated bank-insurance group -- has initiated research coverage of ONWARD Medical with a Buy rating and Target Price of EUR 10.00 per share.

Key Points: 
  • EINDHOVEN, the Netherlands, Feb. 09, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announced that KBC Securities, part of the KBC Group -- a leading Belgian integrated bank-insurance group -- has initiated research coverage of ONWARD Medical with a Buy rating and Target Price of EUR 10.00 per share.
  • This is a premium of 161% to the closing price of EUR 3.83 on February 8, 2024.
  • KBC joins three other banks whose research analysts cover ONWARD Medical, all of which maintain Buy ratings and Target Prices at substantial premiums to the current share price.
  • “KBC Securities’ initiation of coverage reflects strong confidence in our ability to achieve this year’s milestones, which include the planned commercialization of our ARC-EX® platform later this year,” said Dave Marver, CEO of ONWARD Medical.